Description
- CD38 is widely expressed in hematopoietic and non hematopoietic cells and is an important marker of B cells. It is a potential target for multiple myeloma and autoimmune diseases.
- A chimeric CDS that encodes human CD38 transmembrane domain and extracellular domain followed by rat 3’UTR-STOP is inserted right after the exon 2 of rat Cd38 gene. The chimeric CD38 protein expression will be driven by endogenous rat Cd38 promoter, while rat Cd38 gene transcription and translation will be disrupted.
- Rat CD38 was detectable on B cells of wild-type SD rats. Human CD38 was exclusively detectable on B cells of homozygous B-hCD38 rats.
- This product is used to evaluate the pharmacodynamics and safety of CD38 antibody in B cell lymphoma and autoimmune diseases.
Targeting Strategy
Gene targeting strategy for B-hCD38 rats. A chimeric CDS that encodes human CD38 transmembrane domain and extracellular domain followed by rat 3’UTR-STOP is inserted right after the exon 2 of rat Cd38 gene. The chimeric CD38 protein expression will be driven by endogenous rat Cd38 promoter, while rat Cd38 gene transcription and translation will be disrupted.
Protein Expression Analysis
Strain specific CD38 expression analysis in homozygous B-hCD38 rats by flow cytometry. Splenocytes and blood were collected from wild-type SD rats (+/+) and homozygous B-hCD38 rats (H/H). Protein expression was analyzed with anti-rat CD38 antibody (Biolegend, 250505) and anti-human CD38 antibody (Biolegend, 356606) by flow cytometry. Rat CD38 was detectable on B cells of wild-type SD rats. Human CD38 was exclusively detectable on B cells of homozygous B-hCD38 rats.
* When publishing results obtained using this animal model, please acknowledge the source as follows: The animal model [B-hCD38 rats] (Cat# 114418) was purchased from Biocytogen.
